Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jun Shen, Meng Wang, Fan Li, Huanhuan Yan, Rui Wang & Jun Zhou. (2022) Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer. Breast Cancer: Targets and Therapy 14, pages 375-389.
Read now
Read now
Qing She, Yuanyuan Chen, Hong Liu, Jichao Tan & Youhuai Li. (2022) A high level of the long non-coding RNA MCF2L-AS1 is associated with poor prognosis in breast cancer and MCF2L-AS1 activates YAP transcriptional activity to enhance breast cancer proliferation and metastasis. Bioengineered 13:5, pages 13437-13451.
Read now
Read now
Yunchao Xin, Xiaoling Shang, Xiaoran Sun, Guogang Xu, Yachao Liu & Yanbin Liu. (2022) SLC8A1 antisense RNA 1 suppresses papillary thyroid cancer malignant progression via the FUS RNA binding protein (FUS)/NUMB like endocytic adaptor protein (Numbl) axis. Bioengineered 13:5, pages 12572-12582.
Read now
Read now
Ying Fang & Qianqian Yang. (2022) Specificity protein 1-induced serine peptidase inhibitor, Kunitz Type 1 antisense RNA1 regulates colorectal cancer cell proliferation, migration, invasion and apoptosis through targeting heparin binding growth factor via sponging microRNA-214. Bioengineered 13:2, pages 3309-3322.
Read now
Read now
Yabo Liu, Huibo Li, Yanqiu Zhao, Dandan Li, Qian Zhang, Jinyue Fu & Shengjin Fan. (2022) Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia. Bioengineered 13:2, pages 2296-2307.
Read now
Read now
Jun Shen, Meng Wang, Fan Li, Huanhuan Yan & Jun Zhou. (2022) Homeodomain-containing gene 10 contributed to breast cancer malignant behaviors by activating Interleukin-6/Janus kinase 2/Signal transducer and activator of transcription 3 pathway. Bioengineered 13:1, pages 1335-1345.
Read now
Read now
Articles from other publishers (6)
Po-Shuan Huang, Ling-Yu Wang, Yi-Wen Wang, Ming-Ming Tsai, Tzu-Kang Lin, Chia-Jung Liao, Chau-Ting Yeh & Kwang-Huei Lin. (2023) Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer. Cells 12:6, pages 869.
Crossref
Crossref
Maliheh Entezari, Afshin Taheriazam, Sima Orouei, Shayan Fallah, Arezoo Sanaei, Elahe Sadat Hejazi, Amirabbas Kakavand, Shamin Rezaei, Hajar Heidari, Mitra Behroozaghdam, Salman Daneshi, Shokooh Salimimoghadam, Sepideh Mirzaei, Mehrdad Hashemi & Saeed Samarghandian. (2022) LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions. Biomedicine & Pharmacotherapy 154, pages 113609.
Crossref
Crossref
Ivana Samaržija, Marko Tomljanović, Renata Novak Kujundžić & Koraljka Gall Trošelj. (2022) EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies. Cancers 14:19, pages 4761.
Crossref
Crossref
Qian Chen, Xiao He, Bin Li, Jingjing Chen & Xuxia Tang. (2022) Suppression of Long Noncoding RNA SNHG1 Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma via Increasing PARP6 Expression. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-10.
Crossref
Crossref
Deepshikha Singh, Yehuda G. Assaraf & Rajesh N. Gacche. (2022) Long non-coding RNA mediated drug resistance in breast cancer. Drug Resistance Updates 63, pages 100851.
Crossref
Crossref
Hyein Jo, Kyeonghee Shim & Dooil Jeoung. (2022) Potential of the miR-200 Family as a Target for Developing Anti-Cancer Therapeutics. International Journal of Molecular Sciences 23:11, pages 5881.
Crossref
Crossref